Direct interleukin-6 blockade in real-world clinical practice – a path to rationalization of pharmacotherapy and control of rheumatoid arthritis

Interleukin (IL)-6 is a key mediator in the pathogenesis of rheumatoid arthritis (RA). Olokizumab (OKZ, Artlegia®, R-Pharm) is a direct IL-6 inhibitor whose efficacy has been demonstrated in randomized controlled trials, post-marketing studies, and real-world practice. However, different dosing regimens of OKZ and their impact on its usage frequency, as well as on doses of glucocorticoids (GCs) and nonsteroidal anti-inflammatory drugs (NSAIDs), have been insufficiently studied.
Objective: to evaluate the efficacy and safety of OKZ in routine clinical practice, with emphasis on the use of different dosing regimens and concomitant use of GCs and NSAIDs in patients with RA.
Material and methods. In a multicenter retrospective observational program included patients in whom OKZ therapy was initiated in real-world clinical practice from 01.12.2023 to 30.11.2024 with subsequent 12-month follow-up. A total of 1240 adult patients with active RA meeting the 2010 ACR/EULAR criteria were enrolled. Of these, 80.5% were women; median age was 55 years; median RA duration was 87 months; 86.5% of patients were rheumatoid factor positive, 82.7% were positive for anti-cyclic citrullinated peptide antibodies; a high comorbidity burden was noted. Patients with incomplete DAS28-CRP/CDAI data or follow-up <3 months were excluded from the efficacy analysis. Assessments were performed at baseline and at 3, 6, and 12 months.
Results and discussion. At baseline, 89.4% of patients had high/moderate RA activity according to DAS28-CRP. OKZ was prescribed once every 4 weeks in 89.8% of cases; in patients with higher laboratory activity, once every 2 weeks in 10.2% (p<0.01). A marked positive response with achievement of remission/low disease activity according to DAS28-CRP by month 12 was observed in 78.4% of cases. The proportion of patients receiving GCs decreased from 51.3% to 15.7%; median daily GCs dose decreased from 7.5 to 5.0 mg (p<0.05); the proportion of patients continuously using NSAIDs decreased from 32.8% to 1.9%. Adverse events (AEs) were reported in 9.0% of patients (OKZ was discontinued in 4.5%); no new AEs were identified.
Conclusion. In the vast majority of cases, OKZ is used at a dose of 64 mg once every 4 weeks, providing achievement of therapeutic targets in real-world clinical practice in most patients (by month 12 – in 78.4%). In our observation trial the proportion of patients who require every 2 week administration was insignificant and included no more than 3% over 12 months of therapy. Therapy is accompanied by a significant reduction in the need for GCs and NSAIDs.

1. https://www.consultant.ru/document/cons_doc_LAW_495885/8efd5f17af55cb35a770f73937590c642437b7eb/

2. Avci AB, Feist E, Burmester GR. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What Have We Learned? BioDrugs. 2024 Jan;38(1):61-71. doi: 10.1007/s40259-023-00634-1.

3. Aletaha D, Kerschbaumer A, Kastrati K, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Ann Rheum Dis. 2023 Jun;82(6):773-787. doi: 10.1136/ard-2022-222784.

4. Nasonov EL, Feist E. Prospects of interleukin-6 inhibition in rheumatoid arthritis: olokizumab (new monoclonal antibodies to IL-6). Nauchno-prakticheskaya revmatologiya. 2022;60(5):505-518. (In Russ.).

5. Nasonov E, Fatenejad S, Feist E, et al. Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Apr;81(4):469-479. doi: 10.1136/annrheumdis-2021-219876.

6. Smolen JS, Feist E, Fatenejad S, et al. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis. N Engl J Med. 2022 Aug 25;387(8):715-726. doi: 10.1056/NEJMoa2201302.

7. Feist E, Fatenejad S, Grishin S, et al. Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study. Ann Rheum Dis. 2022 Dec;81(12):1661-1668. doi: 10.1136/ard-2022-222630.

8. Feist E, Fleischmann RM, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Ann Rheum Dis. 2024 Oct 21;83(11):1454-1464. doi: 10.1136/ard-2023-225473.

9. Baranov AA, Vinogradova IB, Anoshenkova ON, et al. Management of patients with rheumatoid arthritis in real clinical practice: experience of switching from therapy with an interleukin 6 receptor inhibitor to a direct interleukin 6 inhibitor (olokizumab). Nauchnoprakticheskaya revmatologiya. 2023;61(3): 307-319. (In Russ.).

10. Shesternya PA, Baranov AA, Vinogradova IB, et al. Switching from interleukin-6 receptor inhibitors to the direct interleukin-6 inhibitor olokizumab in patients with rheumatoid arthritis: efficacy and safety during one year of therapy. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2024;18(5):54-64. (In Russ.). doi: 10.14412/1996-7012-2024-5-54-64.

11. Shesternya PA, Zagrebneva AI, Antipova OV, et al. Use of olokizumab, a direct interleukin 6 inhibitor, in the treatment of rheumatoid arthritis: real-world evidence. Modern Rheumatology Journal. 2025;19(2):39-49. (In Russ). doi: 10.14412/1996-7012-2025-2-39-49.

12. https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=f2bc77b4-6298-4b2e-8f37-18e1baa0b63c

13. England BR, Sayles H, Mikuls TR, et al. Validation of the rheumatic disease comorbidity index. Arthritis Care Res (Hoboken). 2015 May;67(6):865-72. doi: 10.1002/acr.22456.

14. Nasonov EL, Karateev DE, Satybaldyev AM, et al. Rheumatoid arthritis in the Russian Federation according to the Russian Register of Patients with Arthritis (Message I). Nauchno-prakticheskaya revmatologiya. 2015;53(5): 472-84. (In Russ.).

15. Domper Arnal MJ, Hijos-Mallada G, Lanas A. Gastrointestinal and cardiovascular adverse events associated with NSAIDs. Expert Opin Drug Saf. 2022 Mar;21(3):373-384. doi: 10.1080/14740338.2021.1965988.

16. Yao TC, Huang YW, Chang SM, et al. Association Between Oral Corticosteroid Bursts and Severe Adverse Events: A Nationwide Population-Based Cohort Study. Ann Intern Med. 2020 Sep 1;173(5):325-330. doi: 10.7326/M20-0432.

17. Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab. 2024 Jun 17;109(7):1657-1683. doi: 10.1210/clinem/dgae250.

18. Kondo M, Yamada H. Drug survival rates of biological disease-modifying antirheumatic drugs and Janus kinase-inhibitor therapy in 801 rheumatoid arthritis patients: a 14 yearretrospective study from a rheumatology clinic in Japan. Mod Rheumatol. 2019 Nov;29(6): 928-935. doi: 10.1080/14397595.2018.1537556.

19. Karateev АЕ, Polishchuk ЕY, Filatova ЕS, et al. Olokizumab effect on chronic pain in rheumatoid arthritis: Results of the PROLOGUE observational study. Int J Rheum Dis. 2024 Oct;27(10):e15320. doi: 10.1111/1756-185X.15320. PMID: 39441547.